Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 6,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CHANGE Study Clear all

Conditions: Distress
Interventions: Integrative hatha yoga and mindful self-compassion; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Nicotine Dependence
Interventions: Sit to Quit, Quit for Life; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease
Interventions: Music therapy, Health education; Behavioral · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 14 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio • Greenville, South Carolina

Conditions: Hyperlipidemias, Overweight and Obesity, Diabetes
Interventions: TeleMOVE!, Culinary Rx; Behavioral
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: stereotactic radiosurgery, magnetic resonance imaging, quality-of-life assessment, Serum Prostate Antigen Test, Digital Rectal Exam, Expanded Prostate Cancer Index Composite; Radiation · Device · Other + 2 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Uterine Fibroids, Uterine Leiomyomas
Interventions: ExAblate 2000; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more

Conditions: Cystic Fibrosis (CF)
Interventions: ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Behavioral Intervention, Educational Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bipolar Disorder
Interventions: Customized Adherence Enhancement (CAE), Enhanced Treatment as Usual (eTAU); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Lorain, Ohio

Conditions: Parkinson's Disease, Exercise Therapy, Cognition
Interventions: PDAE, WAE; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Medication Adherence, Medication Nonadherence, Adverse Drug Event
Interventions: Collaborative nurse-pharmacist counseling; Behavioral
Lead sponsor: Tonia Carr; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pressure Ulcers
Interventions: P500 Mattress; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 19 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Psoriasis
Interventions: Ustekinumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: 16P11.2 Deletion Syndrome, 16p11.2 Duplications, 1Q21.1 Deletion, 1Q21.1 Microduplication Syndrome (Disorder), ACTL6B, ADNP, AHDC1, ANK2, ANKRD11, ARID1B, ASH1L, BCL11A, CHAMP1, CHD2, CHD8, CSNK2A1, CTBP1, CTNNB1 Gene Mutation, CUL3, DDX3X, DNMT3A, DSCAM, DYRK1A, FOXP1, GRIN2A, GRIN2B, HIVEP2-Related Intellectual Disability, HNRNPH2, KATNAL2, KDM5B, KDM6B, KMT2C Gene Mutation, KMT2E, KMT5B, MBD5, MED13L, PACS1, PPP2R5D-Related Intellectual Disability, PTCHD1, REST, SCN2A Encephalopathy, SETBP1 Gene Mutation, SETD5, SMARCA4 Gene Mutation, SMARCC2, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability, TBR1, ARHGEF9, HNRNPU, PPP3CA, PPP2R1A, SLC6A1, 2p16.3 Deletions, 5q35 Deletions, 5q35 Duplications, 7q11.23 Duplications, 15Q13.3 Deletion Syndrome, 16p11.2 Triplications, 16P12.2 Microdeletion, 16P13.11 Microdeletion Syndrome (Disorder), 17Q12 Microdeletion Syndrome (Disorder), 17Q12 Duplication Syndrome, 17Q21.31 Deletion Syndrome, 17q21.3 Duplications, ACTB, ADSL, AFF2, ALDH5A1, ANK3, ARX, ATRX Gene Mutation, AUTS2 Syndrome, BCKDK, BRSK2, CACNA1C, CAPRIN1, CASK, CASZ1, CHD3, CIC, CNOT3, CREBBP Gene Mutation, CSDE1, CTCF, DEAF1, DHCR7, DLG4, EBF3, EHMT1, EP300 Gene Mutation, GIGYF1, GRIN1, GRIN2D, IQSEC2-Related Syndromic Intellectual Disability, IRF2BPL, KANSL1, KCNB1, KDM3B, NEXMIF, KMT2A, MBOAT7, MEIS2, MYT1L, NAA15, NBEA, NCKAP1, NIPBL, NLGN2, NLGN3, NLGN4X, NR4A2, NRXN1, NRXN2, NSD1 Gene Mutation, PHF21A, PHF3, PHIP, PSMD12, RELN, RERE, RFX3, RIMS1, RORB, SCN1A, SETD2 Gene Mutation, SHANK2, SIN3A, SLC9A6, SON, SOX5, SPAST, SRCAP, TAOK1, TANC2, TCF20, TLK2, TRIO, TRIP12, UPF3B, USP9X, VPS13B, WAC, WDFY3, ZBTB20, ZNF292, ZNF462, 2Q37 Deletion Syndrome, 9q34 Duplications, 15q15 Deletions, 15Q24 Deletion, NR3C2, SYNCRIP, 2q37.3 Deletion, 6q16 Deletion, 15q11.2 BP1-BP2 Deletion, 16p13.3 Deletion, 17Q11.2 Microduplication Syndrome (Disorder), 17p13.3, Xq28 Duplication, CLCN4, CSNK2B, DYNC1H1, EIF3F, GNB1, MED13, MEF2C, RALGAPB, SCN1B, YY1, Xp11.22 Duplication, PACS2, MAOA, MAOB, HNRNPC, HNRNPD, HNRNPK, HNRNPR, HNRNPUL2, 5P Deletion Syndrome, TCF7L2 Gene Mutation, HECW2, PPM1D, RNU4-2, SNAP25, FOXP2, ITSN1
Interventions: Not listed
Lead sponsor: Simons Searchlight; Other
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2050
U.S. locations: 2
States / cities: Boston, Massachusetts • Lewisburg, Pennsylvania

Conditions: Burnout, Caregiver, Quality of Life
Interventions: Online Heart-Focused Breathing Intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Glioblastoma (GBM)
Interventions: Ketogenic Diet, Radiation therapy, Temozolomide; Dietary Supplement · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Dental Implants
Interventions: Not listed
Lead sponsor: Keystone Dental, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 8
States / cities: Newport Beach, California • Woodland Hills, California • Oakbrook Terrace, Illinois + 5 more

Conditions: Depression, Unipolar, Fall
Interventions: Behavioral Activation, Fall Prevention, Telephone support; Behavioral · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 50 Years to 100 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Burns
Interventions: bacitracin/xeroform, Polymem; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Sclerosis
Interventions: Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments; Other
Lead sponsor: Anza Memon; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Head and Neck Melanoma
Interventions: fluorescent cRGDY-PEG-Cy5.5-C dots; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 2
States / cities: New York, New York

Conditions: Hypercholesterolemia
Interventions: Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 35 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Interventions: CART-19; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine, filgrastim, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Treatments for Improving Mood in Women Survivors of Interpersonal Violence: A Community-Engaged Study-1.2

Study on Sit to Quit Phone Intervention

MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease

Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Financial Health Educational Program for Increasing Financial Literacy Among Underserved Communities in Western New York

Effectiveness RCT of Customized Adherence Enhancement

Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease

Collaborative Nurse-pharmacist Counseling for Self-administered Biologics

Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

Heart-Focused Breathing in Alzheimer's Disease Caregivers

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Five Year Survival Study Evaluating the Genesis Dental Implant System

Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression

Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds

Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis

Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer